Multifarious Determinants of Cytokine Receptor Signaling Specificity

Advances in Immunology

Volumn 121, Issue , 2014, Pages 1-39

  Moraga, Ignacio ^a   Spangler, Jamie ^a   Mendoza, Juan L ^a   Garcia, K Christopher ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine engineering; Cytokine signaling; Cytokine structure; Functional specificity; Interleukin; Ligand receptor affinity; Receptor trafficking

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA2 INTERFERON; BETA INTERFERON; CYTOKINE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; JANUS KINASE 3; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ARTICLE; COMPLEX FORMATION; CYTOKINE RESPONSE; GEOMETRY; HUMAN; IMMUNOREGULATION; INTRACELLULAR SIGNALING; LIGAND BINDING; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; SURFACE PROPERTY;

CYTOKINE ENGINEERING; CYTOKINE SIGNALING; CYTOKINE STRUCTURE; FUNCTIONAL SPECIFICITY; INTERLEUKIN; LIGAND-RECEPTOR AFFINITY; RECEPTOR TRAFFICKING;

ANIMALS; EPITOPES; HOMEOSTASIS; HUMANS; LIGANDS; PRIMARY CELL CULTURE; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, CYTOKINE; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 84891360395     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800100-4.00001-5     Document Type: Chapter

References (190)

1. Abramovich C., Shulman L.M., Ratovitski E., Harroch S., Tovey M., Eid P., et al. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta. EMBO Journal 1994, 13:5871-5877.
2. Andrews A.L., Holloway J.W., Holgate S.T., Davies D.E. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: Implications for the development of therapeutic targets. Journal of Immunology 2006, 176:7456-7461.
3. Andrews A.L., Holloway J.W., Puddicombe S.M., Holgate S.T., Davies D.E. Kinetic analysis of the interleukin-13 receptor complex. Journal of Biological Chemistry 2002, 277:46073-46078.
4. Avalos B.R., Gasson J.C., Hedvat C., Quan S.G., Baldwin G.C., Weisbart R.H., et al. Human granulocyte colony-stimulating factor: Biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 1990, 75:851-857.
5. Bagley C.J., Woodcock J.M., Hercus T.R., Shannon M.F., Lopez A.F. Interaction of GM-CSF and IL-3 with the common beta-chain of their receptors. Journal of Leukocyte Biology 1995, 57:739-746.
6. Ballinger M.D., Wells J.A. Will any dimer do?. Natural Structural Biology 1998, 5:938-940.
7. Bazan J.F. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochemical and Biophysical Research Communications 1989, 164:788-795.
8. Bazan J.F. Haemopoietic receptors and helical cytokines. Immunology Today 1990, 11:350-354.
9. Becker V., Schilling M., Bachmann J., Baumann U., Raue A., Maiwald T., et al. Covering a broad dynamic range: Information processing at the erythropoietin receptor. Science 2010, 328:1404-1408.
10. Becker V., Sengupta D., Ketteler R., Ullmann G.M., Smith J.C., Klingmuller U. Packing density of the erythropoietin receptor transmembrane domain correlates with amplification of biological responses. Biochemistry 2008, 47:11771-11782.
11. Berndt W.G., Chang D.Z., Smith K.A., Ciardelli T.L. Mutagenic analysis of a receptor contact site on interleukin-2: Preparation of an IL-2 analog with increased potency. Biochemistry 1994, 33:6571-6577.
12. Boder E.T., Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nature Biotechnology 1997, 15:553-557.
13. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: Past, current and future impact on biomedicine. Nature Reviews. Drug Discovery 2007, 6:975-990.
14. Boulanger M.J., Bankovich A.J., Kortemme T., Baker D., Garcia K.C. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Molecular Cell 2003, 12:577-589.
15. Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003, 300:2101-2104.
16. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
17. Braun D.A., Fribourg M., Sealfon S.C. Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. Journal of Biological Chemistry 2013, 288:2986-2993.
18. Brideau-Andersen A.D., Huang X., Sun S.C., Chen T.T., Stark D., Sas I.J., et al. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8269-8274.
19. Brown R.J., Adams J.J., Pelekanos R.A., Wan Y., McKinstry W.J., Palethorpe K., et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nature Structural & Molecular Biology 2005, 12:814-821.
20. Bulut G.B., Sulahian R., Ma Y., Chi N.W., Huang L.J. Ubiquitination regulates the internalization, endolysosomal sorting, and signaling of the erythropoietin receptor. Journal of Biological Chemistry 2011, 286:6449-6457.
21. Chomarat P., Banchereau J. Interleukin-4 and interleukin-13: Their similarities and discrepancies. International Reviews of Immunology 1998, 17:1-52.
22. Constantinescu S.N., Ghaffari S., Lodish H.F. The erythropoietin receptor: Structure, activation and intracellular signal transduction. Trends in Endocrinology and Metabolism 1999, 10:18-23.
23. Constantinescu S.N., Huang L.J., Nam H., Lodish H.F. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Molecular Cell 2001, 7:377-385.
24. Constantinescu S.N., Keren T., Socolovsky M., Nam H., Henis Y.I., Lodish H.F. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:4379-4384.
25. Costa-Pereira A.P., Tininini S., Strobl B., Alonzi T., Schlaak J.F., Is'harc H., et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8043-8047.
26. Croze E., Russell-Harde D., Wagner T.C., Pu H., Pfeffer L.M., Perez H.D. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. Journal of Biological Chemistry 1996, 271:33165-33168.
27. Cunningham B.C., Ultsch M., De Vos A.M., Mulkerrin M.G., Clauser K.R., Wells J.A. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991, 254:821-825.
28. Cunningham B.C., Wells J.A. Minimized proteins. Current Opinion in Structural Biology 1997, 7:457-462.
29. David M., Petricoin E., Benjamin C., Pine R., Weber M.J., Larner A.C. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science 1995, 269:1721-1723.
30. Debinski W., Gibo D.M., Obiri N.I., Kealiher A., Puri R.K. Novel anti-brain tumor cytotoxins specific for cancer cells. Nature Biotechnology 1998, 16:449-453.
31. Delgoffe G.M., Murray P.J., Vignali D.A. Interpreting mixed signals: The cell's cytokine conundrum. Current Opinion in Immunology 2011, 23:632-638.
32. Depper J.M., Leonard W.J., Drogula C., Kronke M., Waldmann T.A., Greene W.C. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:4230-4234.
33. de Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 1992, 255:306-312.
34. Dondi E., Rogge L., Lutfalla G., Uze G., Pellegrini S. Down-modulation of responses to type I IFN upon T cell activation. Journal of Immunology 2003, 170:749-756.
35. Dondi E., Roue G., Yuste V.J., Susin S.A., Pellegrini S. A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. Journal of Immunology 2004, 173:3740-3747.
36. Fellouse F.A., Esaki K., Birtalan S., Raptis D., Cancasci V.J., Koide A., et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. Journal of Molecular Biology 2007, 373:924-940.
37. Francois-Newton V., Magno de Freitas Almeida G., Payelle-Brogard B., Monneron D., Pichard-Garcia L., Piehler J., et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One 2011, 6:e22200.
38. Friedrich K., Kammer W., Erhardt I., Brandlein S., Arnold S., Sebald W. The two subunits of the interleukin-4 receptor mediate independent and distinct patterns of ligand endocytosis. European Journal of Biochemistry 1999, 265:457-465.
39. Fuh G., Colosi P., Wood W.I., Wells J.A. Mechanism-based design of prolactin receptor antagonists. Journal of Biological Chemistry 1993, 268:5376-5381.
40. Fuh G., Cunningham B.C., Fukunaga R., Nagata S., Goeddel D.V., Wells J.A. Rational design of potent antagonists to the human growth hormone receptor. Science 1992, 256:1677-1680.
41. Fujiwara H., Hanissian S.H., Tsytsykova A., Geha R.S. Homodimerization of the human interleukin 4 receptor alpha chain induces Cepsilon germline transcripts in B cells in the absence of the interleukin 2 receptor gamma chain. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:5866-5871.
42. Gauzzi M.C., Barbieri G., Richter M.F., Uze G., Ling L., Fellous M., et al. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:11839-11844.
43. German C.L., Sauer B.M., Howe C.L. The STAT3 beacon: IL-6 recurrently activates STAT 3 from endosomal structures. Experimental Cell Research 2011, 317:1955-1969.
44. Ghislain J., Sussman G., Goelz S., Ling L.E., Fish E.N. Configuration of the interferon-alpha/beta receptor complex determines the context of the biological response. Journal of Biological Chemistry 1995, 270:21785-21792.
45. Gil M.P., Ploquin M.J., Watford W.T., Lee S.H., Kim K., Wang X., et al. Regulating type 1 IFN effects in CD8 T cells during viral infections: Changing STAT4 and STAT1 expression for function. Blood 2012, 120:3718-3728.
46. Gil M.P., Salomon R., Louten J., Biron C.A. Modulation of STAT1 protein levels: A mechanism shaping CD8 T-cell responses in vivo. Blood 2006, 107:987-993.
47. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFNgamma signaling-does it mean JAK-STAT?. Cytokine & Growth Factor Reviews 2008, 19:383-394.
48. Greiser J.S., Stross C., Heinrich P.C., Behrmann I., Hermanns H.M. Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling. Journal of Biological Chemistry 2002, 277:26959-26965.
49. Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nature Reviews. Immunology 2008, 8:533-544.
50. Hansen G., Hercus T.R., McClure B.J., Stomski F.C., Dottore M., Powell J., et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 2008, 134:496-507.
51. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal 2003, 374:1-20.
52. Heller N.M., Qi X., Gesbert F., Keegan A.D. The extracellular and transmembrane domains of the gammaC and interleukin (IL)-13 receptor alpha1 chains, not their cytoplasmic domains, dictate the nature of signaling responses to IL-4 and IL-13. Journal of Biological Chemistry 2012, 287:31948-31961.
53. Heller N.M., Qi X., Junttila I.S., Shirey K.A., Vogel S.N., Paul W.E., et al. Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Science Signaling 2008, 1:ra17.
54. Herrero C., Hu X., Li W.P., Samuels S., Sharif M.N., Kotenko S., et al. Reprogramming of IL-10 activity and signaling by IFN-gamma. Journal of Immunology 2003, 171:5034-5041.
55. Ho H.H., Ivashkiv L.B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. Journal of Biological Chemistry 2006, 281:14111-14118.
56. Huang B., Bates M., Zhuang X. Super-resolution fluorescence microscopy. Annual Review of Biochemistry 2009, 78:993-1016.
57. Huang L.J., Constantinescu S.N., Lodish H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Molecular Cell 2001, 8:1327-1338.
58. Hunter C.A., Kastelein R. New paradigms in inflammation: Where to next?. Immunological Reviews 2008, 226:6-9.
59. Ihle J.N., Witthuhn B.A., Quelle F.W., Yamamoto K., Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annual Review of Immunology 1995, 13:369-398.
60. Irandoust M.I., Aarts L.H., Roovers O., Gits J., Erkeland S.J., Touw I.P. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO Journal 2007, 26:1782-1793.
61. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London B: Biological Sciences 1957, 147:258-267.
62. Ito T., Suzuki S., Kanaji S., Shiraishi H., Ohta S., Arima K., et al. Distinct structural requirements for interleukin-4 (IL-4) and IL-13 binding to the shared IL-13 receptor facilitate cellular tuning of cytokine responsiveness. Journal of Biological Chemistry 2009, 284:24289-24296.
63. Jaitin D.A., Roisman L.C., Jaks E., Gavutis M., Piehler J., Van der Heyden J., et al. Inquiring into the differential action of interferons (IFNs): An IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Molecular and Cellular Biology 2006, 26:1888-1897.
64. Jaitin D.A., Schreiber G. Upregulation of a small subset of genes drives type I interferon-induced antiviral memory. Journal of Interferon & Cytokine Research 2007, 27:653-664.
65. Jones B.C., Logsdon N.J., Walter M.R. Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure 2008, 16:1333-1344.
66. Joshi S., Kaur S., Redig A.J., Goldsborough K., David K., Ueda T., et al. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12097-12102.
67. Junttila I.S., Creusot R.J., Moraga I., Bates D.L., Wong M.T., Alonso M.N., et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nature Chemical Biology 2012, 8:990-998.
68. Junttila I.S., Mizukami K., Dickensheets H., Meier-Schellersheim M., Yamane H., Donnelly R.P., et al. Tuning sensitivity to IL-4 and IL-13: Differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity. Journal of Experimental Medicine 2008, 205:2595-2608.
69. Kalie E., Jaitin D.A., Abramovich R., Schreiber G. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. Journal of Biological Chemistry 2007, 282:11602-11611.
70. Kalie E., Jaitin D.A., Podoplelova Y., Piehler J., Schreiber G. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. Journal of Biological Chemistry 2008, 283:32925-32936.
71. Kang L., Bondensgaard K., Li T., Hartmann R., Hjorth S.A. Rational design of interleukin-21 antagonist through selective elimination of the gammaC binding epitope. Journal of Biological Chemistry 2010, 285:12223-12231.
72. Kaur S., Sassano A., Dolniak B., Joshi S., Majchrzak-Kita B., Baker D.P., et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:4808-4813.
73. Kawahara M., Ogo Y., Tsumoto K., Kumagai I., Ueda H., Nagamune T. Growth control of hybridoma cells with an artificially induced EpoR-gp130 heterodimer. Cytotechnology 2006, 52:171-179.
74. Keeler C., Jablonski E.M., Albert Y.B., Taylor B.D., Myszka D.G., Clevenger C.V., et al. The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry 2007, 46:2398-2410.
75. Kelly-Welch A.E., Hanson E.M., Boothby M.R., Keegan A.D. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003, 300:1527-1528.
76. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. Journal of Experimental Medicine 2005, 202:637-650.
77. Krieg C., Letourneau S., Pantaleo G., Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:11906-11911.
78. Kruse N., Tony H.P., Sebald W. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO Journal 1992, 11:3237-3244.
79. Krutzik P.O., Nolan G.P. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nature Methods 2006, 3:361-368.
80. Kubatzky K.F., Ruan W., Gurezka R., Cohen J., Ketteler R., Watowich S.S., et al. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Current Biology 2001, 11:110-115.
81. Kumar K.G., Krolewski J.J., Fuchs S.Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. Journal of Biological Chemistry 2004, 279:46614-46620.
82. Kurche J.S., Haluszczak C., McWilliams J.A., Sanchez P.J., Kedl R.M. Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. Journal of Immunology 2012, 188:585-593.
83. Lamken P., Lata S., Gavutis M., Piehler J. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. Journal of Molecular Biology 2004, 341:303-318.
84. LaPorte S.L., Juo Z.S., Vaclavikova J., Colf L.A., Qi X., Heller N.M., et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008, 132:259-272.
85. Letourneau S., van Leeuwen E.M., Krieg C., Martin C., Pantaleo G., Sprent J., et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:2171-2176.
86. Levin A.M., Bates D.L., Ring A.M., Krieg C., Lin J.T., Su L., et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484:529-533.
87. Levy D.E., Darnell J.E. Stats: Transcriptional control and biological impact. Nature Reviews. Molecular Cell Biology 2002, 3:651-662.
88. Liang H.E., Reinhardt R.L., Bando J.K., Sullivan B.M., Ho I.C., Locksley R.M. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nature Immunology 2011, 13:58-66.
89. Liao W., Lin J.X., Leonard W.J. IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Current Opinion in Immunology 2011, 23:598-604.
90. Liu W., Brooks C.L. Functional impact of manipulation on the relative orientation of human prolactin receptor domains. Biochemistry 2011, 50:5333-5344.
91. Liu D.V., Maier L.M., Hafler D.A., Wittrup K.D. Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. Journal of Immunotherapy 2009, 32:887-894.
92. Livnah O., Johnson D.L., Stura E.A., Farrell F.X., Barbone F.P., You Y., et al. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Natural Structural Biology 1998, 5:993-1004.
93. Livnah O., Stura E.A., Johnson D.L., Middleton S.A., Mulcahy L.S., Wrighton N.C., et al. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science 1996, 273:464-471.
94. Livnah O., Stura E.A., Middleton S.A., Johnson D.L., Jolliffe L.K., Wilson I.A. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999, 283:987-990.
95. Logsdon N.J., Deshpande A., Harris B.D., Rajashankar K.R., Walter M.R. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:12704-12709.
96. Lowenthal J.W., Castle B.E., Christiansen J., Schreurs J., Rennick D., Arai N., et al. Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. Journal of Immunology 1988, 140:456-464.
97. Lu X., Gross A.W., Lodish H.F. Active conformation of the erythropoietin receptor: Random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. Journal of Biological Chemistry 2006, 281:7002-7011.
98. Malek T.R. The biology of interleukin-2. Annual Review of Immunology 2008, 26:453-479.
99. Marchetti M., Monier M.N., Fradagrada A., Mitchell K., Baychelier F., Eid P., et al. Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors. Molecular Biology of the Cell 2006, 17:2896-2909.
100. Marijanovic Z., Ragimbeau J., van der Heyden J., Uze G., Pellegrini S. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochemical Journal 2007, 407:141-151.
101. Matthews D.J., Topping R.S., Cass R.T., Giebel L.B. A sequential dimerization mechanism for erythropoietin receptor activation. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:9471-9476.
102. McElroy C.A., Dohm J.A., Walsh S.T. Structural and biophysical studies of the human IL-7/IL-7Ralpha complex. Structure 2009, 17:54-65.
103. Meyer L., Deau B., Forejtnikova H., Dumenil D., Margottin-Goguet F., Lacombe C., et al. beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 2007, 109:5215-5222.
104. Moraga I., Harari D., Schreiber G., Uze G., Pellegrini S. Receptor density is key to the alpha2/beta interferon differential activities. Molecular and Cellular Biology 2009, 29:4778-4787.
105. Mosser D.M., Zhang X. Interleukin-10: New perspectives on an old cytokine. Immunological Reviews 2008, 226:205-218.
106. Murray P.J. The JAK-STAT signaling pathway: Input and output integration. Journal of Immunology 2007, 178:2623-2629.
107. Obiri N.I., Debinski W., Leonard W.J., Puri R.K. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. Journal of Biological Chemistry 1995, 270:8797-8804.
108. Ohara J., Paul W.E. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature 1987, 325:537-540.
109. Ohashi H., Maruyama K., Liu Y.C., Yoshimura A. Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:158-162.
110. O'Shea J.J., Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012, 36:542-550.
111. Ozaki K., Leonard W.J. Cytokine and cytokine receptor pleiotropy and redundancy. Journal of Biological Chemistry 2002, 277:29355-29358.
112. Pal G., Kossiakoff A.A., Sidhu S.S. The functional binding epitope of a high affinity variant of human growth hormone mapped by shotgun alanine-scanning mutagenesis: Insights into the mechanisms responsible for improved affinity. Journal of Molecular Biology 2003, 332:195-204.
113. Pang X., Qin S., Zhou H.X. Rationalizing 5000-fold differences in receptor-binding rate constants of four cytokines. Biophysical Journal 2011, 101:1175-1183.
114. Pattyn E., Van Ostade X., Schauvliege L., Verhee A., Kalai M., Vandekerckhove J., et al. Dimerization of the interferon type I receptor IFNaR2-2 is sufficient for induction of interferon effector genes but not for full antiviral activity. Journal of Biological Chemistry 1999, 274:34838-34845.
115. Payelle-Brogard B., Pellegrini S. Biochemical monitoring of the early endocytic traffic of the type I interferon receptor. Journal of Interferon & Cytokine Research 2010, 30:89-98.
116. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annual Review of Immunology 2004, 22:929-979.
117. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunological Reviews 2004, 202:8-32.
118. Pfeffer L.M., Mullersman J.E., Pfeffer S.R., Murti A., Shi W., Yang C.H. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 1997, 276:1418-1420.
119. Pfeffer L.M., Stebbing N., Donner D.B. Cytoskeletal association of human alpha-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:3249-3253.
120. Philo J.S., Aoki K.H., Arakawa T., Narhi L.O., Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 1996, 35:1681-1691.
121. Piehler J., Roisman L.C., Schreiber G. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. Journal of Biological Chemistry 2000, 275:40425-40433.
122. Piehler J., Schreiber G. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. Journal of Molecular Biology 1999, 294:223-237.
123. Piehler J., Thomas C., Christopher Garcia K., Schreiber G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunological Reviews 2012, 250:317-334.
124. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews. Immunology 2005, 5:375-386.
125. Porpiglia E., Hidalgo D., Koulnis M., Tzafriri A.R., Socolovsky M. Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities. PLoS Biology 2012, 10:e1001383.
126. Radtke S., Hermanns H.M., Haan C., Schmitz-Van De Leur H., Gascan H., Heinrich P.C., et al. Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. Journal of Biological Chemistry 2002, 277:11297-11305.
127. Ragimbeau J., Dondi E., Alcover A., Eid P., Uze G., Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO Journal 2003, 22:537-547.
128. Rani M.R., Asthagiri A.R., Singh A., Sizemore N., Sathe S.S., Li X., et al. A role for NF-kappa B in the induction of beta-R1 by interferon-beta. Journal of Biological Chemistry 2001, 276:44365-44368.
129. Reddy C.C., Niyogi S.K., Wells A., Wiley H.S., Lauffenburger D.A. Engineering epidermal growth factor for enhanced mitogenic potency. Nature Biotechnology 1996, 14:1696-1699.
130. Remy I., Wilson I.A., Michnick S.W. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999, 283:990-993.
131. Rickert M., Wang X., Boulanger M.J., Goriatcheva N., Garcia K.C. The structure of interleukin-2 complexed with its alpha receptor. Science 2005, 308:1477-1480.
132. Ring A.M., Lin J.X., Feng D., Mitra S., Rickert M., Bowman G.R., et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nature Immunology 2012, 13:1187-1195.
133. Rocca A., Lamaze C., Subtil A., Dautry-Varsat A. Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments. Molecular Biology of the Cell 2001, 12:1293-1301.
134. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nature Reviews. Immunology 2009, 9:480-490.
135. Roullier V., Clarke S., You C., Pinaud F., Gouzer G.G., Schaible D., et al. High-affinity labeling and tracking of individual histidine-tagged proteins in live cells using Ni2+ tris-nitrilotriacetic acid quantum dot conjugates. Nano Letters 2009, 9:1228-1234.
136. Schaeffer M., Schneiderbauer M., Weidler S., Tavares R., Warmuth M., de Vos G., et al. Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Molecular and Cellular Biology 2001, 21:8068-8081.
137. Schindler U., Hoey T., McKnight S.L. Differentiation of T-helper lymphocytes: Selective regulation by members of the STAT family of transcription factors. Genes to Cells 1996, 1:507-515.
138. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: From interferons to cytokines. Journal of Biological Chemistry 2007, 282:20059-20063.
139. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
140. Shah M., Patel K., Mukhopadhyay S., Xu F., Guo G., Sehgal P.B. Membrane-associated STAT3 and PY-STAT3 in the cytoplasm. Journal of Biological Chemistry 2006, 281:7302-7308.
141. Sharif M.N., Tassiulas I., Hu Y., Mecklenbrauker I., Tarakhovsky A., Ivashkiv L.B. IFN-alpha priming results in a gain of proinflammatory function by IL-10: Implications for systemic lupus erythematosus pathogenesis. Journal of Immunology 2004, 172:6476-6481.
142. Sidhu S.S., Kossiakoff A.A. Exploring and designing protein function with restricted diversity. Current Opinion in Chemical Biology 2007, 11:347-354.
143. Silver J.S., Hunter C.A. gp130 at the nexus of inflammation, autoimmunity, and cancer. Journal of Leukocyte Biology 2010, 88:1145-1156.
144. Slutzki M., Jaitin D.A., Yehezkel T.B., Schreiber G. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity. Journal of Molecular Biology 2006, 360:1019-1030.
145. Staerk J., Defour J.P., Pecquet C., Leroy E., Antoine-Poirel H., Brett I., et al. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO Journal 2011, 30:4398-4413.
146. Stroud R.M., Wells J.A. Mechanistic diversity of cytokine receptor signaling across cell membranes. Science's STKE 2004, 2004:re7.
147. Subramaniam P.S., Khan S.A., Pontzer C.H., Johnson H.M. Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:12270-12274.
148. Subtil A., Delepierre M., Dautry-Varsat A. An alpha-helical signal in the cytosolic domain of the interleukin 2 receptor beta chain mediates sorting towards degradation after endocytosis. Journal of Cell Biology 1997, 136:583-595.
149. Swaminathan K., Flynn P., Reece R.J., Marmorstein R. Crystal structure of a PUT3-DNA complex reveals a novel mechanism for DNA recognition by a protein containing a Zn2Cys6 binuclear cluster. Natural Structural Biology 1997, 4:751-759.
150. Syed R.S., Reid S.W., Li C., Cheetham J.C., Aoki K.H., Liu B., et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998, 395:511-516.
151. Taniguchi T., Fujii-Kuriyama Y., Muramatsu M. Molecular cloning of human interferon cDNA. Proceedings of the National Academy of Sciences of the United States of America 1980, 77:4003-4006.
152. Tassiulas I., Hu X., Ho H., Kashyap Y., Paik P., Hu Y., et al. Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nature Immunology 2004, 5:1181-1189.
153. Tavernier J., Devos R., Cornelis S., Tuypens T., Van der Heyden J., Fiers W., et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991, 66:1175-1184.
154. Thomas J.W., Baum C.M., Hood W.F., Klein B., Monahan J.B., Paik K., et al. Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:3779-3783.
155. Thomas C., Bazan J.F., Garcia K.C. Structure of the activating IL-1 receptor signaling complex. Nature Structural & Molecular Biology 2012, 19:455-457.
156. Thomas C., Moraga I., Levin D., Krutzik P.O., Podoplelova Y., Trejo A., et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011, 146:621-632.
157. Uddin S., Fish E.N., Sher D., Gardziola C., Colamonici O.R., Kellum M., et al. The IRS-pathway operates distinctively from the Stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors. Blood 1997, 90:2574-2582.
158. Uddin S., Yenush L., Sun X.J., Sweet M.E., White M.F., Platanias L.C. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. Journal of Biological Chemistry 1995, 270:15938-15941.
159. Usacheva A., Smith R., Minshall R., Baida G., Seng S., Croze E., et al. The WD motif-containing protein receptor for activated protein kinase C (RACK1) is required for recruitment and activation of signal transducer and activator of transcription 1 through the type I interferon receptor. Journal of Biological Chemistry 2001, 276:22948-22953.
160. Uze G., Bandu M.T., Eid P., Grutter M., Mogensen K.E. Electrostatic interactions in the cellular dynamics of the interferon-receptor complex. European Journal of Biochemistry 1988, 171:683-691.
161. Uze G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: Cloning and expression of its cDNA. Cell 1990, 60:225-234.
162. Uze G., Schreiber G., Piehler J., Pellegrini S. The receptor of the type I interferon family. Current Topics in Microbiology and Immunology 2007, 316:71-95.
163. van Boxel-Dezaire A.H., Rani M.R., Stark G.R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006, 25:361-372.
164. Velazquez L., Fellous M., Stark G.R., Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992, 70:313-322.
165. Verma A., Deb D.K., Sassano A., Uddin S., Varga J., Wickrema A., et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. Journal of Biological Chemistry 2002, 277:7726-7735.
166. Vignali D.A., Kuchroo V.K. IL-12 family cytokines: Immunological playmakers. Nature Immunology 2012, 13:722-728.
167. Wagner T.C., Velichko S., Vogel D., Rani M.R., Leung S., Ransohoff R.M., et al. Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells. Journal of Biological Chemistry 2002, 277:1493-1499.
168. Walter M.R., Windsor W.T., Nagabhushan T.L., Lundell D.J., Lunn C.A., Zauodny P.J., et al. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature 1995, 376:230-235.
169. Wang Y., Fuller G.M. Phosphorylation and internalization of gp130 occur after IL-6 activation of Jak2 kinase in hepatocytes. Molecular Biology of the Cell 1994, 5:819-828.
170. Wang X., Lupardus P., Laporte S.L., Garcia K.C. Structural biology of shared cytokine receptors. Annual Review of Immunology 2009, 27:29-60.
171. Wang X., Rickert M., Garcia K.C. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005, 310:1159-1163.
172. Watowich S.S., Hilton D.J., Lodish H.F. Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Molecular and Cellular Biology 1994, 14:3535-3549.
173. Watowich S.S., Yoshimura A., Longmore G.D., Hilton D.J., Yoshimura Y., Lodish H.F. Homodimerization and constitutive activation of the erythropoietin receptor. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:2140-2144.
174. Wei L., Sandbulte M.R., Thomas P.G., Webby R.J., Homayouni R., Pfeffer L.M. NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity. Journal of Biological Chemistry 2006, 281:11678-11684.
175. Weidemann T., Worch R., Kurgonaite K., Hintersteiner M., Bokel C., Schwille P. Single cell analysis of ligand binding and complex formation of interleukin-4 receptor subunits. Biophysical Journal 2011, 101:2360-2369.
176. Weissenbach J., Chernajovsky Y., Zeevi M., Shulman L., Soreq H., Nir U., et al. Two interferon mRNAs in human fibroblasts: In vitro translation and Escherichia coli cloning studies. Proceedings of the National Academy of Sciences of the United States of America 1980, 77:7152-7156.
177. Wells J.A., de Vos A.M. Hematopoietic receptor complexes. Annual Review of Biochemistry 1996, 65:609-634.
178. Williams L., Bradley L., Smith A., Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. Journal of Immunology 2004, 172:567-576.
179. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunological Reviews 2004, 202:175-190.
180. Wilmes S., Staufenbiel M., Lisse D., Richter C.P., Beutel O., Busch K.B., et al. Triple-color super-resolution imaging of live cells: Resolving submicroscopic receptor organization in the plasma membrane. Angewandte Chemie International Edition in English 2012, 51:4868-4871.
181. Wrighton N.C., Farrell F.X., Chang R., Kashyap A.K., Barbone F.P., Mulcahy L.S., et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273:458-464.
182. Yang C.H., Murti A., Pfeffer S.R., Basu L., Kim J.G., Pfeffer L.M. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:13631-13636.
183. You C., Wilmes S., Beutel O., Lochte S., Podoplelowa Y., Roder F., et al. Self-controlled monofunctionalization of quantum dots for multiplexed protein tracking in live cells. Angewandte Chemie International Edition in English 2010, 49:4108-4112.
184. Zhang J.L., Buehner M., Sebald W. Functional epitope of common gamma chain for interleukin-4 binding. European Journal of Biochemistry 2002, 269:1490-1499.
185. Zhang J.L., Simeonowa I., Wang Y., Sebald W. The high-affinity interaction of human IL-4 and the receptor alpha chain is constituted by two independent binding clusters. Journal of Molecular Biology 2002, 315:399-407.
186. Zhao W., Lee C., Piganis R., Plumlee C., de Weerd N., Hertzog P.J., et al. A conserved IFN-alpha receptor tyrosine motif directs the biological response to type I IFNs. Journal of Immunology 2008, 180:5483-5489.
187. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nature Immunology 2007, 8:457-462.
188. Zhu J., Guo L., Watson C.J., Hu-Li J., Paul W.E. Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. Journal of Immunology 2001, 166:7276-7281.
189. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations (*). Annual Review of Immunology 2010, 28:445-489.
190. Zurawski S.M., Vega F., Huyghe B., Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO Journal 1993, 12:2663-2670.